Article
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells.
Nucleic acids research - 26 Nov 2025
Ribeiro Jonathan, Hansen Kjetil, van Beek Lotte, Stubbs Christopher, Frigola Joan, Talbot Sara, Bentouati Sabrina, Hall James, Wijnhoven Paul W G, Armenia Josh, Schimpl Marianne, Forment Josep V, Albertella Mark R, O'Connor Mark J, Illuzzi Giuditta
Abstract excerpt
Clinically approved PARP inhibitors (PARPi) have shown significant efficacy as monotherapy in homologous recombination repair (HRR)-deficient cancers. PARPi suppress PARP enzymatic activity but can also induce PARP trapping onto DNA lesions, and there is an ongoing debate on which of these properties is key in determining their clinical efficacy as single agents. In this study, we found that the enzymatic...
Read the complete abstract on PubMedTopics
- Poly(ADP-ribose) Polymerase Inhibitors
- Humans
- Poly (ADP-Ribose) Polymerase-1
- BRCA1 Protein
- Female